

# Dose-dependent effect of galangin on fructose-mediated insulin resistance and oxidative events in rat kidney

Allur S. Sivakumar<sup>1</sup>, P. Viswanathan<sup>2</sup>, Carani V. Anuradha<sup>1</sup>

<sup>1</sup>Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalai Nagar, Tamil Nadu, India

<sup>2</sup>Department of Pathology, Faculty of Medicine, Rajah Muthaih Medical College, Annamalai University, Annamalai Nagar, Tamil Nadu, India

Galangin is an antioxidant flavonol present in high concentrations in the rhizome of *Alpinia galanga*. We investigated the effect of galangin on whole-body insulin resistance and kidney oxidative stress in a fructose-induced rat model of metabolic syndrome. Male albino Wistar rats were divided into 6 groups containing six animals each. Groups I and VI received a starch-based control diet, while groups II, III, IV and V were fed a high fructose diet (60 g/100 g). Groups III, IV and V additionally received galangin (50, 100 and 200 µg/kg body weight, respectively) while group VI received 200 µg galangin/kg body weight. At the end of 60 days, fructose-fed rats exhibited insulin resistance, increased levels of peroxidation end products and diminished antioxidant status. Galangin, dose-dependently normalized blood glucose and insulin levels. The minimum effective dose was 100 µg galangin/kg body weight. At this dose, galangin also prevented the development of insulin resistance and the exaggerated the response to oral glucose challenge. The oxidant–antioxidant balance was maintained by galangin. Micro-albuminuria and tubular and glomerular changes observed in fructose-treated rats were significantly prevented by galangin (100 µg/kg body weight). These findings imply that galangin potentiates insulin sensitivity and antioxidant capacity and reduces renal damage in this dietary model of metabolic syndrome.

**Keywords:** fructose, galangin, insulin resistance, kidney, antioxidants

## Introduction

Metabolic syndrome, formerly known as syndrome X, is a multifactorial complex condition that encompasses several clinical and biochemical disorders such as

abdominal obesity, insulin resistance, impaired glucose tolerance, hypertension and dyslipidemia.<sup>1</sup> These disorders are secondary to hyperinsulinemia and decreased insulin responsiveness in the target tissues.<sup>2</sup> Metabolic syndrome and insulin resistance are significant due to the fact that they predispose to diseases of high morbidity like type 2 diabetes, cardiovascular and renal diseases.<sup>3</sup> Experimentally, rats fed high-fructose diet (60 g/100 g) exhibit all the above features and form a well-known rodent model of metabolic syndrome.<sup>4</sup> Fructose feeding is also

---

Correspondence to: Professor C.V. Anuradha, Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar – 608002, Tamilnadu, India  
Tel: +91 4144 239141; Fax: +91 4144 238080;  
E-mail: cvaradha@hotmail.com  
Received 8 April 2010, revised manuscript accepted 17 July 2010

associated with a decline in antioxidants and oxidative damage to proteins and lipids.<sup>5</sup> Studies involving supplementation of antioxidants to fructose-fed rats have witnessed improved insulin sensitivity,<sup>5-7</sup> suggesting that oxidative stress is an instigator of insulin resistance in this model.

Flavonoids are a diverse class of naturally occurring polyphenolic plant compounds that have a variety of important biological activities useful for human health. Galangin (galangin; 3,5,7-trihydroxyflavone) is a flavonol (a class of flavanoids) constituent of *Alpinia galanga* (Zingiberaceae) rhizome and propolis, a natural beehive extract. The dried rhizome of the *Alpinia galanga* is used as a condiment and as an antimicrobial agent. It is used as a local medicine for cough, cold, stomach-ache and diarrhea. This well-known medicinal plant has been used in Asian (Unani) traditional medicine for treating diabetes mellitus.<sup>8</sup> Galangin has been shown to possess antimutagenic, antitumor, anticlastrogenic and antiviral properties. Further, metabolic-modulating effects of galangin are also found in the literature.<sup>9</sup> Such a broad spectrum of action might stem from its antioxidant and anti-inflammatory activities.<sup>10</sup> Although galangin has been subject to such extensive studies, there is a lack of information on the ability of galangin to promote insulin sensitivity and combat oxidative stress in the insulin resistance state. In view of this, we wanted to investigate whether galangin has any beneficial effects on insulin sensitivity and oxidant and antioxidant balance in fructose-fed rat kidney.

## Materials and methods

### Diet

A control diet containing starch and a test diet containing fructose were prepared in our laboratory. The diets were prepared fresh each day.

Control diet contained 60% corn starch, 20% casein, 0.7% methionine, 5% ground nut oil, 10.5% wheat bran, 3.5% salt mixture and 0.2% vitamin mixture. The fructose diet contained all these ingredients except corn starch which was replaced by an equal quantity of fructose.

### Animals and treatment

Male Wistar rats of body weight 150–180 g were obtained from the Central Animal House, Raja Muthiah Medical College, Annamalai Nagar, India. They were housed in an animal house under controlled conditions on a 12-h light/12-h dark cycle.

The animals received a standard pellet diet and water *ad libitum*. The study was approved by the Institutional Animal Ethics Committee of Animal Care, Raja Muthiah Medical College, Annamalai Nagar.

### Experimental design

The animals were divided into six groups ( $n = 6$ ) and were maintained as follows:

- Group 1 CON, animals received the control diet containing starch.
- Group 2 FRU, received the high fructose diet.
- Group 3 FRU + GA1, received the fructose diet and galangin (50 µg/kg body weight).
- Group 4 FRU + GA2, received the fructose diet and galangin (100 µg/kg body weight).
- Group 5 FRU + GA3, received the fructose diet and galangin (200 µg/kg body weight).
- Group 6 CON + GA3, received the control diet and galangin (200 µg/kg body weight).

Food and water were provided *ad libitum* to the animals. Galangin was administered by oral intubation. Food intake and body weight were determined. Animals were maintained in the respective groups for 60 days. On the 59th day of the experimental period, the rats were fasted overnight. Blood samples were collected by sinoocular puncture. Samples were again collected at 120 min after administration of glucose (2 g/kg body weight). The blood glucose concentration was quantitated using a kit from Agappe Diagnostics Pvt. Ltd, Kerala, India. Insulin was assayed using an ELISA kit (Accubind, Monobind Chemicals Ltd, CA, USA). The area-under-curve (AUC) values for glucose and insulin were calculated. Insulin sensitivity was assessed by homeostatic model assessment (HOMA)<sup>11</sup> after species specific adjustment and quantitative insulin check index (QUICKI).<sup>12</sup> The formulae used are given below:

$$\text{HOMA} = \frac{\text{Insulin } (\mu\text{U/dl}) \times \text{Glucose } (\mu\text{U/ml})}{2430} \quad \text{Eq. 1}$$

$$\text{QUICKI} = \frac{1}{[\log (\text{Glucose mg/dl}) + \log (\text{Insulin } \mu\text{U/ml})]} \quad \text{Eq. 2}$$

On the 60th day of experimental period, the animals were fasted overnight and sacrificed by cervical decapitation the next day under anesthesia

**Table 1 Initial and final body weight of experimental animals**

Groups	CON	FRU	FRU + GA <sub>1</sub>	FRU + GA <sub>2</sub>	FRU + GA <sub>3</sub>	CON + GA <sub>3</sub>
Initial body weight (g)	180.3 ± 11.2	175.4 ± 10.8	173.6 ± 11.5	175.2 ± 10.7	178.7 ± 11.2	180.8 ± 11.4
Final body weight (g)	220.5 ± 10.7	250.7 ± 10.7	245.8 ± 9.4	225.9 ± 10.4	235.2 ± 10.5	225.8 ± 11.7

Values are mean ± SD of 6 rats from each group. CON, control rats; FRU, fructose-fed rats; FRU + GA<sub>1</sub>, fructose-fed rats treated with galangin (50 µg/kg body weight/day); FRU + GA<sub>2</sub>, fructose-fed rats treated with galangin (100 µg/kg body weight/day); FRU + GA<sub>3</sub>, fructose-fed rats treated with galangin (200 µg/kg body weight/day); CON + GA<sub>3</sub>, control rats treated with galangin (200 µg/kg body weight/day).

**Table 2 Oral glucose tolerance test in control and experimental animals**

Groups	CON	FRU	FRU + GA <sub>1</sub>	FRU + GA <sub>2</sub>	FRU + GA <sub>3</sub>	CON + GA <sub>3</sub>
0 min	59.9 ± 4.2	122.3 ± 8.7 <sup>a</sup>	98.0 ± 4.3	62.6 ± 3.7 <sup>b</sup>	73.4 ± 4.2	63.4 ± 3.3
60 min	131.7 ± 8.3	181.5 ± 11.2 <sup>a</sup>	169.2 ± 9.3	133.3 ± 9.2 <sup>b</sup>	146.6 ± 9.3	135.5 ± 8.6
120 min	64.9 ± 3.8	128.41 ± 7.6 <sup>a</sup>	104.59 ± 7.4	67.6 ± 4.6 <sup>b</sup>	75.4 ± 5.5	67.4 ± 5.5

Values are mean ± SD of 6 rats from each group. CON, control rats; FRU, fructose-fed rats; FRU + GA<sub>1</sub>, fructose-fed rats treated with galangin (50 µg/kg body weight/day); FRU + GA<sub>2</sub>, fructose-fed rats treated with galangin (100 µg/kg body weight/day); FRU + GA<sub>3</sub>, fructose-fed rats treated with galangin (200 µg/kg body weight/day); CON + GA<sub>3</sub>, control rats treated with galangin (200 µg/kg body weight/day).

<sup>a</sup>Significant as compared to control rats ( $P < 0.05$ ; DMRT).

<sup>b</sup>Significant as compared to fructose-fed rats ( $P < 0.05$ ; DMRT).

(ketamine hydrochloride, 35 mg/kg body weight, i.p.). Blood was collected in tubes containing ethylene diamine tetra acetate (EDTA). The body was cut open and the kidneys excised, washed in ice-cold saline and the homogenate was prepared in cold 0.1 M phosphate buffer, pH 7.4. Plasma was separated by centrifugation at 1500 *g* for 10 min. The red blood cells were washed thrice in physiological saline and used for the preparation of the hemolysate by the method of Dodge *et al.*<sup>13</sup> Assays were done in plasma, hemolysate and kidney homogenate. Animals from each group ( $n = 6$ ) were kept individually in metabolic cages and 24-h urine samples were collected in sealed beakers that contained 0.2 ml of 10 N hydrochloric acid for analysis of proteins.

#### Biochemical assays

##### Measurement of oxidative stress markers

The level of thiobarbituric acid reactive substances (TBARS) in kidney homogenate was estimated by the method of Niehaus and Samuelsson<sup>14</sup> and that of lipid hydroperoxides (LHPs) by the method of Jiang *et al.*<sup>15</sup> Protein carbonyl (PC) content was determined by the method of Levine *et al.*<sup>16</sup> and urinary protein was measured using a kit from Qualigens (Mumbai, India). Hemoglobin in hemolysate<sup>17</sup> and protein<sup>18</sup> in kidney were assayed.

##### Measurement of antioxidants

The activities of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) and the

levels of reduced glutathione (GSH), ascorbic acid (vitamin C),  $\alpha$ -tocopherol (vitamin E) and protein were assayed in the kidney homogenate by methods outlined elsewhere.<sup>19</sup>

##### Histopathology

For histopathology, the kidneys were removed and fixed in 10% buffered formalin. They were later processed, sectioned to a thickness of 4–5 µm and stained with hematoxylin and eosin.

##### Statistical analysis

Data are expressed as mean ± SD ( $n = 6$ ). Statistical evaluation was carried out by one-way analysis of variance (ANOVA) followed by Duncan's Multiple Range Test (DMRT) for multiple comparisons. A value of  $P < 0.05$  was considered statistically significant.

## Results

Initial and final body weights of animals are shown in Table 1. Weight gain was observed in all groups at the end of the experimental period. However, the final body weights did not significantly vary between the groups. Food intake and fluid intake during the experimental period were similar between the groups.

Table 2 shows the blood glucose values in response to the oral glucose load in each group. The glucose levels in fructose-fed rats were higher than all the

**Table 3** Glucose, insulin, homeostatic model assessment (HOMA), quantitative insulin check index (QUICKI), AUC<sub>glucose</sub> and AUC<sub>insulin</sub> in experimental animals

Parameters	CON	FRU	FRU + GA1	FRU + GA2	FRU + GA3	CON + GA3
Glucose (mg/dl)	69.8 ± 3.6	130.6 ± 12.5 <sup>a</sup>	105.3 ± 7.4	73.8 ± 5.7 <sup>b</sup>	86.6 ± 6.4	70.5 ± 4.2
Insulin (U/ml)	30.2 ± 3.0	68.6 ± 5.8 <sup>a</sup>	52.4 ± 4.6	33.5 ± 2.4 <sup>b</sup>	43.6 ± 2.6	30.3 ± 2.7
HOMA	1.04 ± 0.06	3.1 ± 0.2 <sup>a</sup>	2.25 ± 0.4	1.05 ± 0.06 <sup>b</sup>	1.55 ± 0.12	0.94 ± 0.05
QUICKI	0.30 ± 0.02	0.25 ± 0.01 <sup>a</sup>	0.26 ± 0.01	0.29 ± 0.01 <sup>b</sup>	0.28 ± 0.01	0.30 ± 0.02
AUC <sub>glucose</sub> (mg/ml/min)	131.7 ± 7.5	181.5 ± 8.5 <sup>a</sup>	169.2 ± 6.9	135.5 ± 5.8 <sup>b</sup>	146.6 ± 6.7	133.3 ± 7.6
AUC <sub>insulin</sub> (μU/ml/min)	43.6 ± 3.1	86.5 ± 6.5 <sup>a</sup>	75.3 ± 5.7	55.3 ± 3.8 <sup>b</sup>	64.3 ± 4.8	42.3 ± 2.6

Values are mean ± SD of 6 rats from each group. CON, control rats; FRU, fructose-fed rats; FRU + GA1, fructose-fed rats treated with galangin (50 μg/kg body weight/day); FRU + GA2, fructose-fed rats treated with galangin (100 μg/kg body weight/day); FRU + GA3, fructose-fed rats treated with galangin (200 μg/kg body weight/day).

<sup>a</sup>Significant as compared with control rats ( $P < 0.05$ ; DMRT).

<sup>b</sup>Significant as compared with fructose-fed rats ( $P < 0.05$ ; DMRT).

AUC, area under the curve, HOMA and QUICKI are calculated by formulae given in Materials and Methods.

**Table 4** Lipid hydroperoxides (LHP), thiobarbituric acid reactive substances (TBARS), protein carbonyl (PC) in plasma and kidney

Parameters	CON	FRU	FRU + GA	CON + GA
LHP*				
Plasma	0.67 ± 0.08	1.11 ± 0.14 <sup>a</sup>	0.76 ± 0.05 <sup>b</sup>	0.66 ± 0.04
Kidney	1.72 ± 0.07	3.02 ± 0.21	1.81 ± 0.15 <sup>b</sup>	1.39 ± 0.05
TBARS*				
Plasma	3.06 ± 0.25	5.92 ± 0.29 <sup>a</sup>	3.95 ± 0.21 <sup>b</sup>	3.04 ± 0.27
Kidney	1.89 ± 0.12	3.17 ± 0.21 <sup>a</sup>	2.04 ± 0.11 <sup>b</sup>	1.85 ± 0.09
PC*				
Plasma	1.89 ± 0.09	3.79 ± 0.15 <sup>a</sup>	2.08 ± 0.18 <sup>b</sup>	1.87 ± 0.07
Kidney	1.74 ± 0.06	2.32 ± 0.11 <sup>a</sup>	1.81 ± 0.56 <sup>b</sup>	1.72 ± 0.06

Values are mean ± SD of 6 rats from each group. CON, control rats; FRU, fructose-fed rats; FRU + GA, fructose-fed rats treated with galangin (100 μg/kg body weight/day); CON + GA, control rats treated with galangin (100 μg/kg body weight/day).

<sup>a</sup>Significant as compared with control rats ( $P < 0.05$ ; DMRT).

<sup>b</sup>Significant as compared with fructose-fed rats ( $P < 0.05$ ; DMRT).

\*mmol/dl for plasma; μmol/mg protein for kidney.

other groups. Here again, we observed that GA<sub>2</sub> and GA<sub>3</sub> had more promising effects than GA<sub>1</sub> in reducing glucose levels.

Table 3 shows glucose, insulin, HOMA, QUICKI and AUC<sub>glucose</sub> and AUC<sub>insulin</sub> values. Insulin resistance was observed in fructose-fed rats as measured by HOMA and QUICKI values which were significantly altered in fructose-fed rats when compared to control rats. The values were close to normal in GA<sub>2</sub> and GA<sub>3</sub> treated fructose-fed rats. Both AUC<sub>glucose</sub> and AUC<sub>insulin</sub> levels were significantly higher in fructose-fed rats than in control rats. GA<sub>2</sub>-treated fructose-fed rats showed significantly reduced values of AUC<sub>glucose</sub> and AUC<sub>insulin</sub> as compared to those of untreated fructose-fed rats (Table 3). Fructose-diet induced hyperinsulinemia and hyperglycemia were completely normalized in GA<sub>2</sub> and GA<sub>3</sub> groups. As we found that GA<sub>2</sub> and GA<sub>3</sub> were equally effective, we fixed the minimum dosage of galangin (GA<sub>2</sub>, 100 μg) for further study.

Oxidative stress parameters, TBARS, HP and PC in plasma and kidney are listed in Table 4. The levels of TBARS, HP and PC were significantly higher in animals fed fructose diet than those fed control diet. However, galangin-treated fructose-fed rats showed significantly lower levels as compared to fructose-fed rats.

The activities of SOD, CAT and GPx in the hemolysate and kidney and the levels of GSH, vitamins C and E in circulation and kidney of fructose diet-fed animals were significantly decreased ( $P < 0.05$ ) as compared to control animals Tables 5 and 6. However, galangin treatment prevented the detrimental effects of fructose by uplifting the levels of antioxidants.

The levels of urinary protein (mg/dl) were CON, 1.05 ± 0.07; FRU, 2.00 ± 0.2; FRU + GA, 1.10 ± 0.07 and CON + GA, 1.04 ± 0.05. Treatment of fructose-fed animals with galangin reduced proteinuria

Figure 1 (A–J) shows the histology of kidney of

**Table 5 Levels of enzymatic antioxidants in hemolysate, kidney**

Parameters	CON	FRU	FRU + GA	CON + GA
SOD <sup>A</sup>				
Hemolysate	3.8 ± 0.26	2.5 ± 0.18 <sup>a</sup>	3.1 ± 0.18 <sup>b</sup>	3.8 ± 0.25
Kidney	4.1 ± 0.32	2.8 ± 0.18 <sup>a</sup>	3.9 ± 0.29 <sup>b</sup>	4.2 ± 0.30
CAT <sup>B</sup>				
Hemolysate	187.9 ± 1.4	141.9 ± 1.5 <sup>a</sup>	182.5 ± 10.3 <sup>b</sup>	188.4 ± 11.4
Kidney	62.4 ± 6.5	47.3 ± 2.4 <sup>a</sup>	58.4 ± 4.4 <sup>b</sup>	63.7 ± 1.5
GPx <sup>C</sup>				
Hemolysate	6.7 ± 0.36	4.2 ± 0.43 <sup>a</sup>	6.1 ± 0.52 <sup>b</sup>	6.7 ± 0.62
Kidney	10.6 ± 1.3	6.4 ± 0.3 <sup>a</sup>	9.6 ± 0.9 <sup>b</sup>	10.9 ± 0.9

Values are mean ± SD of 6 rats from each group. CON, control rats; FRU, fructose-fed rats; FRU + GA, fructose-fed rats treated with galangin (100 µg/kg body weight/day); CON + GA, control rats treated with galangin (100 µg/kg body weight/day).

<sup>a</sup>Significant as compared with control rats ( $P < 0.05$ ; DMRT).

<sup>b</sup>Significant as compared with fructose-fed rats ( $P < 0.05$ ; DMRT).

<sup>A</sup>Unit/mg Hb for hemolysate; amount of enzymes which gave 50% inhibition NBT reduction/mg protein.

<sup>B</sup>µmol of H<sub>2</sub>O<sub>2</sub> consumed/min/mg Hb for hemolysate; µmol of H<sub>2</sub>O<sub>2</sub> consumed/min/mg protein for kidney.

<sup>C</sup>µmol of GSH utilized/min/mg Hb for hemolysate; µmol of GSH utilized/min/mg protein for kidney.

**Table 6 Levels of non-enzymatic antioxidants in plasma and kidney of experimental groups**

Parameters	CON	FRU	FRU + GA	CON + GA
Vitamin C*				
Plasma	171.2 ± 9.4	108.7 ± 8.9 <sup>a</sup>	160.3 ± 11.1 <sup>b</sup>	172.1 ± 11.5
Kidney	45.3 ± 3.2	24.7 ± 1.2 <sup>a</sup>	38.7 ± 1.4 <sup>b</sup>	45.9 ± 0.05
Vitamin E*				
Plasma	30.4 ± 1.4	18.8 ± 1.5 <sup>a</sup>	26.4 ± 1.8 <sup>b</sup>	29.2 ± 1.6
Kidney	26.5 ± 1.8	15.4 ± 0.2 <sup>a</sup>	22.5 ± 1.9 <sup>b</sup>	26.9 ± 1.4
GSH*				
Plasma	898.5 ± 6.2	582.5 ± 4.2 <sup>a</sup>	793.5 ± 6.2 <sup>b</sup>	908.8 ± 7.5
Kidney	6.3 ± 0.5	4.5 ± 0.3 <sup>a</sup>	5.6 ± 0.3 <sup>b</sup>	6.8 ± 0.4

Values are mean ± SD of 6 rats from each group. CON, control rats; FRU, fructose-fed rats; FRU + GA, fructose-fed rats treated with galangin (100 µg/kg body weight/day); CON + GA, control rats treated with galangin (100 µg/kg body weight/day).

<sup>a</sup>Significant as compared with control rats ( $P < 0.05$ ; DMRT).

<sup>b</sup>Significant as compared with fructose-fed rats ( $P < 0.05$ ; DMRT).

\*µmol/l for plasma; µmol/mg protein for kidney.

experimental animals. The sections from control rats exhibit normal glomeruli and tubules (A,B). Fatty infiltration is absent. Figure 1C,D represents kidney sections from fructose-fed group, which reveals segmental glomerulonephritis, proteinaceous material, vessel wall thickening and inflammatory cell infiltration in the parenchyma. Sections of fructose-treated animals show extensive changes involving almost all the glomeruli (C,D). Renal damage is only

partially mitigated in FRU+GA<sub>1</sub> groups (E,F). The severity of renal injury induced by fructose is lowered by galangin (100 µg/kg body weight; Fig. 1G,H). About 75% of the glomeruli appear normal. Fatty infiltration and inflammation are reduced. Despite being a high dose, GA<sub>3</sub> was not as effective as GA<sub>2</sub> in controlling the glomerular changes. Renal damage is still noticed involving more than 50% of the glomeruli in FRU+GA<sub>3</sub> (Fig. 1I). However, GA<sub>3</sub> administration

**Figure 1** (see opposite page) **Histopathology of kidney using hematoxylin and eosin (A–J; ×20).** Sections from control rat show glomeruli surrounded by Bowman's space and capsules; tubules are within normal limits (A,B). (C,D) represent kidney sections of high fructose-fed rats. The arrows in (C) show focal segmental glomerulonephritis and the glomerulus containing proteinaceous material. In (D), the arrows show fat accumulation in the cells lining the tubules. (E,F) represent the kidney sections of high fructose diet-treated rats with low dose (F+GA<sub>1</sub>); The arrows show fat accumulation in tubules (E). In (F), the arrows show hyaline cast within the tubules. (G,H) represent sections from rats treated with middle dose (F+GA<sub>2</sub>). Accumulation of fat vacuoles is minimized within tubular cells. (H) shows near normal glomeruli. (I) Kidney section from animals treated with high dose (F+GA<sub>3</sub>); the arrow shows the focal segmental glomerulonephritis and inflammatory cell infiltrate around Bowman's space. (J) Section of a control rat treated with high dose (C+GA<sub>3</sub>) featuring normal glomeruli and tubules






Figure 1 (see next page)

to control rat has no deleterious effect on renal histology (Fig. 1J).

## Discussion

Literature survey revealed that the insulin-sensitizing action and antioxidant-rejuvenating potential of galangin in fructose-fed rats have not been explored. In this vein, the results of the present study are the first evidence to demonstrate that galangin effectively controls fructose-induced metabolic changes, promotes insulin sensitivity and simultaneously activates the antioxidant system.

The development of insulin resistance in fructose-fed rats is well-documented in the literature.<sup>4-7</sup> Fructose-induced pathology in rodents has been recommended as an experimental model to assess the therapeutic efficacy of putative insulin sensitizers from natural sources.<sup>6,20</sup> Confirming earlier studies,<sup>6,7</sup> high fructose feeding in rats for 2 months led to fasting hyperglycemia, hypertriglyceridemia, hyperinsulinemia, insulin resistance, glucose intolerance and oxidative stress in this study. Defects in insulin receptor gene expression and post-receptor events are noted in fructose-fed rats which are responsible for the development of insulin resistance.<sup>21</sup> Since kidney is a target organ for insulin action, we chose this tissue for our study.

Fructose-fed rats showed increased oxidative stress and inefficient antioxidant system as compared to control rats. This finding is consistent with the documented literature.<sup>5-7</sup> The development of oxidative stress is attributed to the rise in glucose level and formation of glucose derived-free radicals by processes like auto-oxidation and non-enzymatic glycation.<sup>22</sup> Further, an increase in the catabolism of fructose could be associated with the cellular ATP depletion that can increase the susceptibility of cells to lipid peroxidation.

Reduction in antioxidant defense mechanisms and altered redox ratio (GSH/GSSG) have also been reported in fructose-fed rats that contribute to oxidative stress. Reduction in antioxidants could be due to increased utilization to scavenge the free radicals, and/or decreased regeneration from their oxidized forms. Some investigators<sup>23</sup> have observed increase in vitamin E levels while reduction has also been observed.<sup>24</sup> These differences may be due to variation in the duration of treatment or animal strains used. From our results, we suggest that depletion in vitamin E is due to increased utilization and is responsible for the increased susceptibility to

lipid peroxidation. Reactive oxygen species (ROS) can damage and reduce the activity of antioxidant enzymes such as CAT and GPx.<sup>25</sup> Decreased SOD activity in fructose-fed rats may be due to enhanced glycation of enzyme protein.<sup>26</sup>

Improved whole body insulin sensitivity and antioxidant status by galangin are the major outcome of the study. Galangin was effective in controlling hyperglycemia and hyperinsulinemia at all three doses tested. A dose-dependent effect at a concentrations of 50 and 100 µg/kg body weight was observed. However, at 200 µg/kg body weight, a similar effect as that of 100 µg/kg body weight was observed. Histological data on renal architecture are consistent with the dose-dependent effect on glycemia and insulin sensitivity parameters. Thus GA<sub>2</sub> was fixed as the minimum effective concentration for studies thereafter.

Flavonoid antioxidants generally act in biological system via their radical-scavenging ability which terminate the chain reaction of lipid peroxidation. A number of publications on the antioxidative effects of galangin are available.<sup>27-30</sup> Galangin is a unique antioxidant in that it has free radical scavenging effect without a pro-oxidant effect. Galangin has a 2,3-double bond, a 3-hydroxy group in the C-ring and two hydroxyl groups in the A-ring but no hydroxyl in the B-ring. These chemical attributes of galangin account for its potent anti-oxidative and ROS-scavenging activities. Galangin is potent scavenger of singlet oxygen and superoxide anion due to its redox properties.<sup>31</sup> Being a low toxic dietary compound, galangin is suggested to be an adjuvant in treating malignancies.<sup>32</sup>

As oxidative stress has been suggested as one of the detrimental effects of fructose, the antioxidant potential may be a mechanism by which galangin prevented fructose-induced insulin resistance. Therapy with antioxidants like vitamin E, lipoic acid and taurine promotes insulin sensitivity in fructose-fed rats,<sup>5,7,8</sup> while treatment with an insulin sensitizer, metformin, improves the antioxidant potential and reduces oxidative stress.<sup>33</sup>

In this study, galangin appears to have a parallel effect on both insulin sensitivity and antioxidant rejuvenation. This suggests that both these processes are inter-related mechanisms. This could be true, since recent reports indicate that ROS can disturb the insulin signal cascade by activation of transcription factors, pro-inflammatory cytokines and C-Jun N-terminal amino kinase pathways.<sup>34</sup> These, in turn, activate serine phosphorylation rather than tyrosine phosphorylation of insulin receptor and insulin



receptor substrates and thereby the downstream events are affected. Further, Araki *et al.*<sup>35</sup> noted that insulin receptor gene expression requires activation of certain transcription factors that depend on GSH and redox homeostasis for efficient action. Thus, we suggest that galangin, by uplifting the antioxidant concentration, could not only protect the cells from ROS and but also might activate insulin receptor gene expression and, thereby, insulin signaling.

Although galangin seems to be a useful therapeutic agent, galangin is shown to be a substrate of cytochrome P450 that could be transformed successively to kempferol and then to quercetin and could exert toxicity in V79 Chinese hamster cells.<sup>36</sup> Whether galangin exerts such mutagenicity *in vivo* at these doses needs to be tested in order to establish the net effect of this compound.

The antioxidant action of galangin, could be one mechanism for its insulin sensitivity effects. However, further studies on the effects of galangin on other aspects such as insulin signaling and lipid and glucose metabolism must also be considered in future. It is of interest to note that Matsui *et al.*<sup>37</sup> reported that galangin has inhibitory action to intestinal maltase activity and this activity is responsible for the hypoglycemic activity of Rhei Rhizoma extract, in which galangin is the major constituent. Thus, studies in this area are necessary to explore the multiple mechanisms of galangin action in this model.

For the first time, we show that galangin (100 µg/kg body weight) reduces fructose-induced insulin resistance and oxidative damage in kidney. This was verified by improved insulin sensitivity indices, reduced lipid and protein damage and enriched antioxidant potential. One of the important effects of insulin on kidney is sodium re-absorption in proximal tubules and defect in renal sodium handling has been documented in fructose-fed rats.<sup>38</sup> Additional studies on the effect of galangin on renal tubular function and structure and blood pressure are currently underway in our laboratory.

## Conclusions

The present study provides new data on the promising potential of galangin as an adjuvant for the prevention and/or management of the metabolic syndrome and also offers credentials to the traditional claim on the anti-diabetic efficacy of *Alpinia galanga* rhizome.

## References

1. Wajchenberg BL, Malerbi DA, Rocha MS, Lerario AC, Santomauro AT. Syndrome X: a syndrome of insulin resistance. Epidemiological and clinical evidence. *Diabetes Metab Rev* 1994; **10**: 19–29.
2. Isomaa B, Almgren P, Tuomi T *et al.* Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001; **24**: 683–689.
3. Elliot SS, Keint NL, Stern JS, Teff K, Havel PJ. Fructose weight gain and the insulin resistance syndrome. *Am J Clin Nutr* 2002; **76**: 911–922.
4. Basciano H, Federico L, Adeli A. Fructose, insulin resistance and metabolic dyslipidemia. *Nutr Metab* 2005; **2**: 5.
5. Faure P, Rossini E, Lafond JL, Richard MJ, Favier A, Halimi S. Vitamin E improves the free radical defense system potential and insulin sensitivity of rats fed high fructose diets. *J Nutr* 1997; **127**: 103–107.
6. Xi L, Qian Z, Xu G *et al.* Beneficial impact of crocetin, a carotenoid from saffron, on insulin sensitivity in fructose-fed rats. *J Nutr Biochem* 2007; **18**: 64–72.
7. Thirunavukkarasu T, Anitha Nandhini AT, Anuradha CV. Cardiac lipids and antioxidant status in high fructose rats and the effect of  $\alpha$ -lipoic acid. *Nutr Metab Cardiovasc Dis* 2004; **14**: 351–357.
8. Raffaele C, Nicola M. Inhibitory effect of the plant flavonoid galangin on rat vas deferens *in vitro*. *Life Sci* 2003; **72**: 2993–3001.
9. Shih H, Pickwell GV, Quattrochi LC. Differential effects of flavonoid compounds on tumor promoter-induced activation of human CYP1 A2 enhancer. *Arch Biochem Biophys* 2000; **373**: 287–294.
10. Havsteen BH. Flavonoids, a class of natural products of high pharmacological potency. *Biochem Pharmacol* 1983; **32**: 1141–1148.
11. Cacho J, Sevillano J, De Castro J, Herrera E, Ramos MP. Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague–Dawley rats. *Am J Physiol* 2008; **295**: E1269–E1276.
12. Katz A, Nambi SS, Mather K *et al.* Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J Clin Endocrinol Metab* 2000; **85**: 2402–2410.
13. Dodge JT, Mitchell G, Hanaban DJ. The preparation and chemical characteristics of haemoglobin free ghosts of human red cells. *Arch Biochem Biophys* 1963; **180**: 119–130.
14. Nieuhaus WG, Samuelson S. Formation of malondialdehyde from phospholipids arachidonate during microsomal lipid peroxidation. *Eur J Biol Chem* 1968; **6**: 126–130.
15. Jiang ZY, Hunt JV, Wolf SP. Detection of lipid hydroperoxides using the FOX method. *Anal Biochem* 1992; **202**: 384–389.
16. Levine RL, Garland, Oliver CNL. Determination of carbonyl content in oxidatively modified proteins. *Methods Enzymol* 1990; **186**: 464–478.
17. Drabkin DL, Austin JM. Spectrophotometric contents for common haemoglobin derivatives in human, dog and rabbit blood. *J Biol Chem* 1932; **98**: 719–733.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951; **193**: 265–275.
19. Anitha Nandhini AT, Balakrishnan SD, Anuradha CV. Taurine modulates antioxidant potential and control lipid peroxidation in the aorta high fructose-fed rats. *J Biochem Mol Biol Biophys* 2002; **6**: 129–133.
20. Reddy SS, Ramatholisamma P, Karuna R, Saralakumari D. Preventive effect of *Tinospora cordifolia* against high-fructose diet-induced insulin resistance and oxidative stress in male Wistar rats. *Food Chem Toxicol* 2009; **47**: 2224–2229.
21. Bezerra RM, Ueno M, Silva MS, Tavaves DQ, Carvlho CR, Saad MJ. A high fructose diet affects the early step of insulin action in muscle and liver rats. *J Nutr* 2000; **130**: 1531–1535.
22. Wolff SP, Dean RT. Glucose autooxidation and protein modification. The potential role of autooxidative glycation in diabetes. *J Biochem* 1987; **245**: 243–250.
23. Faure P, Rossini E, Lafond JL, Richard MJ, Favier A, Halimis. Vitamin E improves the free radical defense system potential and insulin sensitivity of rats fed high fructose diets. *Nut Meta* 1996; 103–107.
24. Senthil E, Malarvili T. The protective action of *Dolichous riflorus*. L in fructose fed rats. *J Cell Tissue Res* 2009; **9**: 1872–1830.
25. Datta K, Sinha S, Chattopadhyay P. Reactive oxygen species in health and diseases. *Natl Med J India* 2000; **13**: 304–310.
26. Oda A, Bannai C, Yamoka T, Kotari T, Matsushima T, Yamashita K. Inactivation of Cu, Zn–superoxide dismutase by *in vitro* glycosylation in erythrocytes of diabetic patients. *Horm Metab Res* 1994; **26**: 1–4.
27. So FV, Guthrie N, Chambers AF, Carroll KK. Inhibition of proliferation



- of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. *Cancer Lett* 1997; **112**: 127–133.
28. Wall ME, Wani MC, Manikumar G et al. Plant antimutagenic agents. 2. Flavonoids. *J Nat Products* 1988; **51**: 1084–1091.
29. Cholbi MR, Paya M, Alcaraz MJ. Inhibitory effects of phenolic compounds on CCl<sub>4</sub>-induced microsomal lipid peroxidation. *Experientia* 1991; **47**: 195–199.
30. Laskar RA, Sk I, Roy N, Begum NA. Antioxidant activity of Indian propolis and its chemical constituent. *Food Chem* 2010; **122**: 233–237.
31. Ebringer L, Dobias J, Krajovi J, Polonyi J, Krikova L, Lahitova N. Antimutagens reduce ofloxacin-induced bleaching in *Euglena gracilis*. *Mutat Res* 1996; **359**: 85–93.
32. Tolomeo M, Grimaudo S, Di Cristina A et al. Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells. *Cancer Lett* 2008; **265**: 289–297.
33. Srividhya S, Anuradha CV. Metformin improves liver antioxidant potential in rats feed a high fructose diet. *Asia Pacific J Clin Nutr* 2002; **11**: 319–322.
34. Evens JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and cell dysfunction? *Diabetes* 2003; **52**: 1–8.
35. Araki E, Murakami T, Shirotani T. A cluster of four Sp 1 binding sites required for efficient expression of the human insulin receptor gene. *J Biol Chem* 1991; **6**: 3944–3948.
36. Silva D, Rodrigues AS, Gaspar J, Laires A, Rueff J. Metabolism of galangin by rat cytochromes P450: relevance to the genotoxicity of galangin. *Mutat Res* 1997; **393**: 247–257.
37. Matsui T, Kobayashi M, Hayashida S, Matsumoto K. Lutcolin, a flavone, does not suppress postprandial glucose absorption through an inhibition of alpha-glucosidase action. *Biosci Biotechnol Biochem* 2002; **66**: 689–692.
38. Catena C, Cavarape A, Novello M, Giacchetti G. Insulin receptors and renal sodium handling in hypertensive fructose-fed rats. *Kidney Int* 2003; **64**: 2163–2171.

## Addendum

**DOI 10.1179/135100010X12826446921824**

The information that the work published in 'Neuzil J et al. (2007) Mitochondria transmit apoptotic signals in cardiomyocyte-like cells and isolated hearts exposed to experimental ischemia-reperfusion injury. *Redox Report* **12**, 148–162', and 'Zobalova R et al. (2008) Daxx inhibits stress-induced apoptosis in cardiac myocytes. *Redox Rep* **13**, 263-270' were supported in part by a grant from the Grant Agency of the Czech Republic (305/07/1008) was accidentally omitted.